Kyohei Muguruma
Overview
Explore the profile of Kyohei Muguruma including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
53
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muguruma K, Fukuda A, Shida H, Taguchi A, Takayama K, Taniguchi A, et al.
Chem Pharm Bull (Tokyo)
. 2024 Sep;
72(9):831-837.
PMID: 39313388
Mid-sized cyclic peptides are a promising modality for modern drug discovery. Their larger interaction area coupled with an appropriate secondary structure is more suitable than small molecules for binding to...
2.
Imai K, Muguruma K, Nakamura A, Kusakari Y, Chang T, Pradipta A, et al.
Angew Chem Int Ed Engl
. 2024 Jul;
63(43):e202411225.
PMID: 38989662
Methods for producing drugs directly at the cancer site, particularly using bioorthogonal metal catalysts, are being explored to mitigate the side effects of therapy. Albumin-based artificial metalloenzymes (ArMs) catalyze reactions...
3.
Ode Y, Pradipta A, Ahmadi P, Ishiwata A, Nakamura A, Egawa Y, et al.
Chem Sci
. 2023 Aug;
14(30):8054-8060.
PMID: 37538829
Targeted α-particle therapy (TAT) is an attractive alternative to conventional therapy for cancer treatment. Among the available radionuclides considered for TAT, astatine-211 (At) attached to a cancer-targeting molecule appears very...
4.
X-Ray Conformation and Structure-Activity Relationships of MA026, a Reversible Tight Junction Opener
Mukaiyama M, Uchiyama C, Fukuda A, Nakazawa Y, Kuramochi Y, Shibata Y, et al.
J Med Chem
. 2023 Jun;
66(13):8717-8724.
PMID: 37352439
MA026, a cyclic lipodepsipeptide, opens the tight junction (TJ) probably via binding to claudin-1. We reported that (1) TJ-opening activity is dependent on the amino acid sequence order at Glu10-Leu11;...
5.
Yamada K, Muguruma K, Tanaka K
Adv Carbohydr Chem Biochem
. 2022 Dec;
82:11-34.
PMID: 36470648
The concept of "therapeutic in vivo synthetic chemistry" refers to chemical synthesis in living systems using new-to-nature reactions for the treatment or diagnosis of diseases. This review summarizes our development...
6.
Chang T, Nasibullin I, Muguruma K, Kusakari Y, Shimoda T, Tanaka K
Bioorg Med Chem
. 2022 Sep;
73:117005.
PMID: 36150343
Recently, the development of abiotic metal-mediated drug delivery has been significant growth in the fields of anticancer approach and biomedical application. However, the intrinsic toxicity of abiotic metal catalysts makes...
7.
Pradipta A, Ahmadi P, Terashima K, Muguruma K, Fujii M, Ichino T, et al.
Chem Sci
. 2022 Mar;
12(15):5438-5449.
PMID: 35340932
Cytotoxic anticancer drugs used in chemotherapy are often antiproliferative agents that preferentially kill rapidly growing cancer cells. Their mechanism relies mainly on the enhanced proliferation rate of cancer cells and...
8.
Ahmadi P, Muguruma K, Chang T, Tamura S, Tsubokura K, Egawa Y, et al.
Chem Sci
. 2021 Oct;
12(37):12266-12273.
PMID: 34603656
Selective cell tagging (SeCT) therapy is a strategy for labeling a targeted cell with certain chemical moieties a catalytic chemical transformation in order to elicit a therapeutic effect. Herein, we...
9.
Sasaki K, Muguruma K, Osawa R, Fukuda A, Taniguchi A, Kishimura A, et al.
RSC Med Chem
. 2021 May;
12(3):406-409.
PMID: 34046623
Antibody-recruiting molecules (ARMs) are bispecific molecules composed of an antibody-binding motif and a target-binding motif that redirect endogenous antibodies to target cells to elicit immune responses. To enhance the translational...
10.
Muguruma K, Osawa R, Fukuda A, Ishikawa N, Fujita K, Taguchi A, et al.
ChemMedChem
. 2021 Feb;
16(11):1813-1820.
PMID: 33594831
Immunoglobulin G (IgG)-binding peptides such as 15-IgBP are convenient tools for the site-specific modification of antibodies and the preparation of homogeneous antibody-drug conjugates. A peptide such as 15-IgBP can be...